Colorectal Cancer Screening and Quality of Colonoscopy: Where Are We Now?CME/ABIM MOC/CE
|
|
- Shon Clark
- 5 years ago
- Views:
Transcription
1 Colorectal Cancer Screening and Quality of Colonoscopy: Where Are We Now?CME/ABIM MOC/CE Supported by an independent educational grant from Aries Pharmaceuticals Pg.1
2 Colorectal Cancer Screening and Quality of Colonoscopy: Where Are We Now? CME/ABIM MOC/CE This article is a CME/ABIM MOC/CE certified activity. To earn credit for this activity visit: CME Released: 3/25/2018; Valid for credit through: 3/25/2019 Target Audience This activity is intended for gastroenterologists, emergency medicine physicians, and infectious disease (ID)/HIV specialists. Goal The goal of this activity is to improve clinicians knowledge regarding guidelines and available tools for colorectal cancer (CRC) screening, quality indicators for colonoscopy, and technologies that can improve detection of precancerous polyps. Learning Objectives Upon completion of this activity, participants will have increased knowledge regarding the: Recommendations for colorectal cancer (CRC) screening Relationship between adenoma detection rate (ADR) and the risk for CRC New technologies for improving ADRs in CRC screening Accreditation Statement In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. For Physicians Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity. ABIM MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity. For Nurses Awarded 0.50 contact hour(s) of continuing nursing education for RNs and APNs; 0 contact hours are in the area of pharmacology. Pg.2
3 Instructions for Participation and Credit There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board. This activity is designed to be completed within the time designated on page 2; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on page 2. To receive AMA PRA Category 1 Credit, you must receive a minimum score of 75% on the post-test. Follow these steps to earn CME/CE credit*: 1. Read the target audience, learning objectives, and author disclosures. 2. Study the educational content online or printed out. 3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming. You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker. *The credit that you receive is based on your user profile. Hardware/Software Requirements To access activities, users will need: A computer with an Internet connection. Internet Explorer 8.x or higher, the latest versions of Firefox or Safari, or any other W3C standards compliant browser. Adobe Flash Player and/or an HTML5 capable browser may be required for video or audio playback. Occasionally other additional software may be required such as PowerPoint or Adobe Acrobat Reader. Disclosures Roderick Smith, MS Scientific Director, Medscape, LLC Disclosure: Roderick Smith, MS, has disclosed no relevant financial relationships. Amy Bernard, MS, BSN, RN-BC Lead Nurse Planner, Medscape, LLC Disclosure: Amy Bernard, MS, BSN, RN-BC, has disclosed no relevant financial relationships. Pg.3
4 Colorectal Cancer Screening and Quality of Colonoscopy: Where Are We Now? CME/ABIM MOC/CE Hello. I m Douglas Rex, professor of medicine at the Indiana University School of Medicine and director of endoscopy at Indiana University Hospital. Welcome to this program titled CRC Screening and Quality of Colonoscopy: Where Are We Now? During this program, we will have a discussion of investigational agents not approved by the US Food and Drug Administration (FDA) for use in the United States at the time of recording. Pg.4
5 Colorectal cancer (CRC) is still a major problem in the United States. First, the good news: although there are still many cases, the incidence of CRC has been declining for decades. From 1985, the year that Ronald Reagan was diagnosed with CRC, up until about 2000, the rate of decline in incidence was approximately 1% to 2% per year. After 2000, the rate of decline increased to 3% to 4% annually, which coincided with the widespread adoption of screening colonoscopy in the United States. [1] Other factors have contributed to reduced CRC incidence, such as reduction in cigarette smoking. We have this very positive trend in declining CRC incidence rates but only in people aged 50 and older, which is the general screening population. For reasons that are not clear, incidence rates are increasing in people under age 50, which has everyone concerned. Presently in clinical practice, the only individuals we screen for CRC who are under age 50 are those with a positive family history. However, there is a lot of discussion about whether we should move the screening age for average-risk persons to below age 50. That conversation is likely to continue. Now we are going to talk about polyps. Polyps are a very important part of this discussion because in CRC we have the opportunity to not only identify early cancers, and thereby prevent mortality, but actually prevent the disease from developing. As screeners and as gastroenterologists who are colonoscopists, it is very important that we understand the 2 main types of precancerous lesions in the colon: the polyps and the flat lesions. Pg.5
6 Colorectal Cancer Screening and Quality of Colonoscopy: Where Are We Now? CME/ABIM MOC/CE The overwhelming majority of colon cancers arise from these polyps, which are highly prevalent. Very high-level detectors performing colonoscopy will find 1 or more precancerous lesions in half of people aged 50 and older; however, only about 5% of these individuals will develop CRC. Obviously, the great majority of these precancerous lesions will never actually turn into cancer. Nevertheless, because we cannot predict which polyps will become cancerous, it is important that we find them and remove them. That is one of the fundamental strategies for preventing CRC. [1-3] Every clinician who does CRC screening should understand that there are 2 major classes of precancerous lesions in the colon. One of them is the one that you heard so much about in medical school: the adenomas. I like to refer to them as conventional adenomas. These lesions are uniformly dysplastic. To say that there is a dysplastic conventional adenoma is essentially redundant. The pathologist should characterize the dysplasia as either high grade or low grade. The overwhelming majority of adenomas are low grade; as the size of the adenoma increases, so does their risk of being high grade, and high grade is a step closer to cancer. [2] The other way we see polyps characterized on histopathology reports is according to their villosity. Lesions with more than 25% villous elements are termed tubulovillous and those with more than 75% villous elements are villous. In general, villous adenomas are much less common than tubular adenomas, tend to be larger, and are more likely to have high-grade dysplasia. [2] Pg.6
7 Conventional adenomas are fairly evenly distributed throughout the colon. Adenomas that are subtle and more difficult to detect, due to a flat or depressed morphology, are more likely to be found in the proximal colon. [2] This is a very important point. You may have heard that with colonoscopy, we are actually more effective at preventing cancer originating in the left side of the colon than cancer originating in the right side of the colon. This may be because these more subtle and difficult to detect lesions are more prevalent in the proximal colon. As I mentioned, the conventional adenomas are all dysplastic. A term you will hear sometimes in practice is the so-called advanced adenoma -- a lesion that is 1 cm or larger or has high-grade dysplasia or villous elements. [2] Part of the reason that is important is because our noninvasive screening tests, which we will discuss, do not actually target all adenomas. There are just too many adenomas, so if we tried to find every adenoma, including the small ones, everyone undergoing noninvasive screening would need a follow-up colonoscopy. Instead, we focus on the adenomas that are larger, the so-called advanced adenomas. Pg.7
8 Colorectal Cancer Screening and Quality of Colonoscopy: Where Are We Now? CME/ABIM MOC/CE Here are 2 images of conventional adenomas. These images were taken by using blue light. This is referred to as narrow-band imaging (NBI), which is a part of the visible light spectrum that is used to illuminate the colon. On the left is a very broad, flat lesion, and on the right, there are 2 tiny adenomas. One of the things you will notice is that when illuminated with blue light, the adenomas look brown. If you look closely, you will see there are tiny brown lines all over the surface of these lesions; these are blood vessels. These vessels are important when we talk about screening because when they get larger, conventional adenomas can be detected by the fecal immunochemical test (FIT). The FIT is pretty good for detecting conventional adenomas. However, it does not detect serrated lesions at all because they do not have these blood vessels on their surface. We will come back to that shortly. This segues into our second major class of major precancerous polyps: the serrated lesions. Here is the classification of the 3 major groups of serrated lesions. The first one is the hyperplastic polyps. These are mostly very small lesions found in the rectal sigmoid colon and, in particular, the distal colon. Hyperplastic polyps are not considered precancerous. [2] Pg.8
9 However, 2 categories in the serrated class are considered precancerous. Far and away the most important one is the sessile serrated polyp (SSP), often also called the sessile serrated adenoma. The terms are virtually synonymous. I prefer the term SSP because, as we learned, all of the conventional adenomas are dysplastic. If I were to ask you whether the SSPs or sessile serrated adenomas are dysplastic, you might be tempted to say yes, especially if I was using the term sessile serrated adenoma. However, the overwhelming majority of these lesions have virtually no dysplasia histologically yet are considered precancerous. [2] The pathologist should designate an SSP as being without cytological dysplasia or with cytological dysplasia. SSPs with cytological dysplasia are much less common than are SSPs without. If you were to look at an SSP with cytological dysplasia under the microscope, you would see is a segment of the polyp that looks like a conventional adenoma and is actually dysplastic. This is a more advanced stage, closer to cancer. The final lesion subtype, the traditional serrated adenoma, is very uncommon. Unlike the SSPs, which are located primarily in the proximal colon, traditional serrated adenomas are found primarily in the distal colon. Traditional serrated adenomas are dysplastic lesions that tend to be bulky and are sometimes pedunculated. Often, they are mistaken by community pathologists for tubulovillous conventional adenomas. [2] Many gastroenterologists who perform a lot of colonoscopies never see the term traditional serrated adenoma on a colonoscopy report because the subtype is so rare. Pg.9
10 Colorectal Cancer Screening and Quality of Colonoscopy: Where Are We Now? CME/ABIM MOC/CE SSPs and traditional serrated adenomas are thought to account for approximately 15% to 30% of colon cancers. This is a smaller percentage than is found for the conventional adenomas, which account for the overwhelming majority of colon cancers. The SSPs are a relatively recent discovery, so both endoscopists and pathologists are still becoming familiar with them. Expert colonoscopists should find SSPs in about 8% to 9% of screening colonoscopies. Again, the SSPs are going to be distributed more toward the proximal colon. [2] Here are a couple of endoscopic images of SSPs using NBI. In the left image, you can see a very small, flat SSP in the proximal colon. In the right image is a somewhat irregular, much larger lesion. SSPs can be quite large. They also tend to be quite flat and, for that reason, can be difficult to detect. Computed tomography (CT) colonography or virtual colonoscopy is almost useless for the detection of SSPs because of their flat morphology. You will notice the near absence of blood vessels on the surface of these polyps. The FIT, which detects blood, is essentially useless for the detection of SSPs. The FIT-fecal DNA test, which we will talk about later, will detect some of these lesions. This may be because the FIT-fecal DNA test contains hypermethylation markers. The pathway of the SSP is hypermethylation, and hypermethylation is one of the mechanisms via which these polyps progress toward cancer. Pg.10
11 So, what is CRC screening? We gastroenterologists talk about it as the process of finding early cancers and precancerous lesions in patients who are asymptomatic and who have never had detected cancer or polyps. Screening is not the same as surveillance -- surveillance refers to the interval use of colonoscopy in people who have already had cancer or precancerous lesions. As soon as you have had a precancerous polyp or cancer, you now are in the world of surveillance. It is very important for clinicians to understand the different screening systems and how to decide which to use in their patients. [2] If we look at CRC screening on a nationwide or regional basis, there are 2 main ways it gets done. One is opportunistic screening, which refers to the interaction between a provider and a patient. It is a nonsystematic method and, in fact, is how CRC screening is done in most of the United States. Programmatic screening is done within a large healthcare system or even a national healthcare system. For example, Australia, the United Kingdom, and several European countries have programmatic colon cancer screening. This means that the healthcare system is generally offering screening systematically to the entire population. Programmatic CRC screening is considered more effective than opportunistic screening. We generally do not have programmatic CRC screening in the United States, except within large healthcare systems like Kaiser Permanente in California. [2] Pg.11
12 Colorectal Cancer Screening and Quality of Colonoscopy: Where Are We Now? CME/ABIM MOC/CE For office-based opportunistic screening, there is a lot of discussion about what is the best method. There are 3 different approaches to offering screening, but we do not yet have comparative data on them, so it is important for primary care physicians (PCPs) to think about how they want to do this. One approach is the so-called multiple options -- you present the options to the patient and he or she decides which one has the right combination of effectiveness, risk, and cost. It has been shown that offering more than 2 options does not increase adherence, so usually we tell people to pick the 2 best options. My preferences are colonoscopy and FIT, but we will come back to that. [2] Sequential testing is commonly used in the United States. With this method, the physician offers the best test first to the patient. Often, it is colonoscopy. If the patient agrees, you are done. If the patient says no, you move on to the next best test and continue down the list of options until the patient finds something with which he or she can agree. [2] Risk-stratified screenings refers to the idea that we have 80 million people in the United States who have risk for developing CRC but, in fact, the range of risk is quite wide. For example, you might offer a woman in her 50s a less invasive screening test because her pretest probability of having adenomas is lower. In this case, you might use FIT or another noninvasive test. For a man at age 60 or a woman at age 65, who is at higher risk for adenomas, you would offer colonoscopy. That is the concept of risk-stratified screening. There is a rationale for each of these screening approaches, and any of them is acceptable. [2] Pg.12
13 What are our screening options? Often, CRC screening tests are delineated between noninvasive and invasive tests. Noninvasive tests include the FIT and FIT-fecal DNA test. There is also a blood test, which we will discuss. The invasive tests include colonoscopy, flexible sigmoidoscopy, and CT colonography. [2,4] The FIT is a very important test because it has a number of advantages: it is inexpensive, has 80% sensitivity for cancer, detects 30% to 40% of large adenomas, and has excellent specificity; only about every 4 of every 100 patients will have a false-positive response to the FIT. One of the main drawbacks of this test it that is has to be done annually, which can be difficult in office practice if you are not part of a large healthcare system, as I alluded to earlier. FIT also has no sensitivity for serrated lesions. We are likely to detect serrated lesions using FIT only if the patient also has conventional adenomas. [2,4] Pg.13
14 Colorectal Cancer Screening and Quality of Colonoscopy: Where Are We Now? CME/ABIM MOC/CE A test we see advertised on TV is the FIT-fecal DNA test (Cologuard ). This test combines blood and DNA biomarkers and detects about 92% of CRCs and about 60% of large adenomas. It has approximately 40% sensitivity for large SSPs. In comparison, FIT alone does not detect any of these lesions. The drawbacks of the FIT-fecal DNA test are that it is rather expensive and has lower specificity than FIT, particularly in older patients. This is because we become more hypermethylated with age. In people older than 65 years, you can get false-positive rates in the range of 15% to 20%, which is rather high. However, this test is performed only every 3 years. If you have an annual false-positive rate of 4% with annual FIT, you may approach the false-positive rate of the FIT-fecal DNA test. [2] There is also the first FDA approved blood test for CRC screening, the Septin 9 DNA test (Epi procolon ). [5] This test has poor sensitivity for cancer and has no sensitivity for detecting precancerous polyps. It is expensive, and the optimal frequency of use is uncertain. The specificity is 80%, meaning that 1 of every 5 patients has a false-positive result. If you perform this test annually, after 5 years you will need for the entire population to undergo colonoscopy. Therefore, we need some improvements in this test before it can be recommended for routine use. It is presently indicated only for patients who have a poor history of compliance with other CRC screening modalities. [2,5] Pg.14
15 Colonoscopy is considered the gold standard for CRC screening and is often the first test offered sequentially. It is the best screening test for detecting CRC and precancerous lesions and is the only screening method offered at 10-year intervals. Colonoscopy has improved dramatically during the past 20 to 30 years. We are likely to see, even in my lifetime, that 1 or 2 negative colonoscopy examinations may confer lifetime protection for some patients. The downsides of colonoscopy are that it has the highest rate of complications, requires bowel preparation, and is operator dependent, which I will come back to. [2,4] Flexible sigmoidoscopy is a very good test. There are several randomized controlled trials showing that it reduces mortality from cancer in the distal colon. It also is relatively inexpensive, requires less bowel preparation than colonoscopy, and does not require sedation. Flexible sigmoidoscopy is recommended at 5- to 10-year intervals but is most often performed every 5 years. However, because it does not provide good protection against right-sided colon cancer, its use has declined dramatically in recent years. [2] Pg.15
16 Colorectal Cancer Screening and Quality of Colonoscopy: Where Are We Now? CME/ABIM MOC/CE The US Multi-Society Task Force (USMSTF), which is composed of the major gastrointestinal (GI) societies, has different recommendation tiers for CRC tests. In tier 3, you see that the Septin 9, the blood test, is not recommended. Capsule colonoscopy, which has comparable sensitivity to CT colonography and is a pretty good test, is also recommended as tier 3 -- that is, it would be the last recommendation. This is because the bowel preparation is quite difficult and because, unfortunately, the test is usually not reimbursed by insurance. [2] Let s talk about the tier 1 and tier 2 tests. This schematic suggests that the tier 1 tests are offered first. No matter how you offer CRC screening, the 2 main options are colonoscopy every 10 years and annual FIT. Where you are offering multiple options, it is probably best in most cases to start with these 2 options. If you are using sequential screening, you would probably start with colonoscopy. If the patient declines, you go on to the FIT. We talked about how you might use these tests in the risk-stratified approach. If the patient declines both tests, then tier 2 tests should be offered. [2] As I mentioned previously, there is a lot of discussion about the FIT-fecal DNA test that is being marketed directly to consumers. Patients who see the TV ads may come in and ask you about this test and ask you to order it. Flexible sigmoidoscopy, as I said, has really fallen off the radar. CT colonography has been around since 1994, yet has had little impact on screening. This is because it requires bowel preparation, it is not very sensitive, and we have seen recent data showing that it does not detect SSPs. [2] Pg.16
17 For the general population, we want to begin CRC screening at age 50. In African Americans, it is age 45. African Americans get more colon cancer and at a younger age, so we try to adjust for those factors. We talked about how to offer screening and that colonoscopy and FIT should be the first-tier options. As I mentioned, the one population in which we have decreased screening age in practice is in those with a family history of colon cancer. [2] How do you evaluate family history? We want to count cancers or advanced adenomas. This means if a patient tells you that his or her father or sister had polyps but you do not actually know whether it was an advanced lesion, it should probably not be counted as a positive family history. On the other hand, if you have the pathology report documenting an advanced lesion or if the patient tells you that his or her father had surgery for polyps, you can probably assume it was an advanced adenoma. Pg.17
18 Colorectal Cancer Screening and Quality of Colonoscopy: Where Are We Now? CME/ABIM MOC/CE Advanced adenomas and cancers are counted the same. We focus on 2 questions: Was the patient s relative who had an advanced adenoma and cancer a first-degree relative, meaning a parent, sibling, or child? At what age was the relative diagnosed? For a patient with the most common history of a first-degree relative with cancer or advanced adenoma who diagnosed after age 60, our guidelines now say to recommend CRC screening to the patient starting at age 40. Your screening options would be the same as they would be for an average-risk person: colonoscopy every 10 years or annual FIT. In the case of CRC or an advanced adenoma in either 2 first-degree relatives diagnosed at any age or 1 first-degree relative diagnosed before the age of 60 years, the recommendation is colonoscopy every 5 years starting 10 years before the age at which the youngest relative was diagnosed or at age 40, whichever is earlier. [2] Let s talk about the role of the PCP versus the specialist in CRC screening. In general, the role of the PCP is to recommend CRC screening, perform high-quality FIT, and ensure that there is a system in place for follow-up with the patient. The PCP also needs to ensure that positive noninvasive test results are referred to a GI specialist for colonoscopy and to refer screening patients for colonoscopy at the appropriate age. The role of the gastroenterologist is to provide high-quality colonoscopy. [2] Pg.18
19 I want to now move on to colonoscopy and return to the issue of operator dependence. Operator dependence is relevant to a number of different tests. In radiology, for example, we say that ultrasound (US) is much more operator dependent than CT. With CT, the patient moves through the machine while holding his or her breath, and then the radiologist reads the study. US requires an operator who knows how to use the US probe to obtain the correct images. Colonoscopy is like US except even more so. One of the questions that everybody wants to know is: how can I get a good colonoscopy performed for my patients, for myself, and for my family? Operator dependence applies to everything about colonoscopy: detection of cancer and polyps, selection of surveillance intervals, and how effectively polyps are resected. [2] We have a measure that we believe is the best way to determine the performance and skill of the colonoscopist -- in other words, one who is really good at finding precancerous lesions in the colon -- the adenoma detection rate (ADR). We now recommend that everyone performing screening colonoscopies measure and know their ADR. We recommend that patients ask a prospective colonoscopist for his or her ADR and that endoscopists be willing to provide it. The ADR has been endorsed by the professional GI societies and by the Centers for Medicaid and Medicare Services (CMS) as a quality standard for colonoscopy. Pg.19
20 Colorectal Cancer Screening and Quality of Colonoscopy: Where Are We Now? CME/ABIM MOC/CE Recommendations state that the proportion of screening colonoscopies that detect 1 or more conventional adenomas in a general screening population (patients aged 50 or older) be 25% or greater. If you are screening a population that is shifted more toward 1 sex -- for example, perhaps a female endoscopist who has many female patients -- an adjustment should be made for that. We adjust this recommendation only for the patient s age and sex, as these have been shown to be powerful predictors of the patient s risk for developing cancer after a colonoscopy. [2,6] In a large data set from Kaiser Permanente in California, 712 CRCs developed after screening colonoscopy (interval cancers). [7] You can see that 136 gastroenterologists were evaluated in the study and that their ADRs vary quite widely, from 7.4% to 52.5%. This really illustrates how operator dependent colonoscopy is. This study showed that for each 1% increase in a physician s ADR, there was a 3% reduction in the risk for developing interval CRC and a 5% reduction in the risk of a fatal interval CRC. [7] Another screening study from Poland validated this concept, so we know that the ADR is an extremely important quality endpoint for endoscopists. [8] Pg.20
21 A variety of factors can affect the ADR and can be improved. Endoscopists can become better educated about the appearance of subtle lesions in the colon and can become better at performing a more effective examination, such as looking behind nooks and crannies, haustral folds, and valves in the colon, to find lesions hidden from easy view during withdrawal. Just the process of reporting the ADR to colonoscopists seems to improve their performance. We know that effective bowel preparation, particularly taking half or even all the preparation on the day of examination, is also helpful. [6] In the United States, gastroenterologists generally have very high cecal intubation rates, so this is not much of a problem. We get into a lot of variation in withdrawal technique -- some endoscopists withdraw too quickly or do not examine areas that are difficult to access. The right colon, as I have mentioned, is subject to a higher rate of cancers occurring after colonoscopy. So, it is becoming common for gastroenterologists to examine the right colon twice, either performing a second examination in the forward view or via retroflexion. Pg.21
22 Colorectal Cancer Screening and Quality of Colonoscopy: Where Are We Now? CME/ABIM MOC/CE We also have devices and techniques that can help improve ADRs. For example, there are ways of highlighting lesions or exposing more of the mucosa. High definition (HD) is one way of highlighting the mucosa, and it has been used increasingly since the early 2000s. [9] HD colonoscopy has been shown to increase the ADR compared with standard-definition colonoscopy, although not necessarily the detection of advanced adenomas. [9] In practical terms, the modern therapeutic colonoscopist has to have an HD instrument, and all the instruments currently sold and purchased should be HD. Electronic chromoendoscopy refers to shining a special light on the colon or using a computer to process the image. The purpose is to highlight blood vessels in a different color and enhance contrast between the polyp and normal tissue. Chromoendoscopy means spraying dye onto the colon during the procedure. Unfortunately, this is a tedious process, so it is used primarily in patients with inflammatory bowel disease and not much in routine colonoscopy. In addition, there are the devices that will better enable you to visualize the mucosa, which I will discuss. [9] Pg.22
23 Here are 2 photographs showing NBI. These are conventional adenomas. The colon looks either greenish or brownish, and the mucus looks pink instead of yellow. The blood vessels, the little brown lines, are highlighted. NBI can help detect very flat lesions, at least with some of the newer, brighter forms. The older, darker forms of NBI were generally not shown to be effective. Overall, I would have to say that chromoendoscopy is routinely used in clinical practice to improve polyp detection. However, the newer, brighter forms, such as NBI and blue light imaging, have been positive in initial studies and warrant further investigation. One of the new ways of getting dye more easily onto the colon is to take it orally with the bowel preparation. These are a couple of photographs of lesions highlighted with methylene blue MMXä. Many gastroenterologists are familiar with MMX technology because of MMX 5-aminosalicycitate or MMX budesonide. Methylene blue is a vital stain. In some cases, it is taken up more by the polyps than by the surrounding tissue, like these flat polyps in the left image; in other instances, it is taken up more by the normal mucosa. You can see that the flat lesion in the center of the image on the right is actually understained. However, it is the contrast between the lesion and the normal mucosa that really improves visualization. Methylene blue MMX is currently under FDA review for its potential use in screening colonoscopy. Pg.23
24 Colorectal Cancer Screening and Quality of Colonoscopy: Where Are We Now? CME/ABIM MOC/CE We are also seeing more interest in fold-flattening devices. The left image is of Endocuffä, and the right image is of EndoRingsä. These devices fit over the tip of the scope. After you pass the scope into the cecum, you use the little fingers or rings to flatten the haustral folds. It is like reaching between the folds of a drape and pulling it flat. Endocuff Vision (on the left) and the first Endocuff, which had 2 rings of fingers, have been studied extensively. In a randomized study of 498 patients who underwent CRC screening with colonoscopy, Endocuff improved the ADR by 8% vs standard colonoscopy and increased the number of adenomas detected per patient by 86%. [6] Pg.24
25 I have reviewed some of the key aspects of CRC screening. Remember that there are 2 main types of precancerous lesions: the conventional adenomas and the serrated lesions. These lesions differ in appearance, in their propensity to bleed, and in their location in the colon. It is critical for PCPs to encourage CRC screening, as it is the only form of screening that receives a grade A recommendation from the US Preventive Services Task Force. The 2 first-tier tests are colonoscopy every 10 years and annual FIT. It is also important for PCPs to understand the pros and cons of the FIT-fecal DNA test because some patients who see the direct-to-consumer advertising will come in and ask about it. We want to get the best colonoscopy we can for our patients. The whole purpose of colonoscopy is to prevent our patients from getting CRC. To achieve that goal, colonoscopists need to measure and achieve high levels of quality. Thank you for participating in this activity. I hope it helped improve your understanding about screening for CRC, and the tools we have available to accomplish this very important aspect of preventive care. Pg.25
26 Colorectal Cancer Screening and Quality of Colonoscopy: Where Are We Now? CME/ABIM MOC/CE References 1. American Cancer Society. Colorectal cancer facts & figures Atlanta, GA: American Cancer Society; colorectal-cancer-facts-and-figures pdf. Accessed March 6, Rex DK, Boland R, Dominitz JA, et al. Colorectal cancer screening: recommendations for physicians and patients from the US Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol. 2017;112: Esplin E, Snyder MP. Genomic era diagnosis and management of hereditary and sporadic colon cancer. World J Clin Oncol. 2014;5: Issa IA, Noureddine M. Colorectal cancer screening: an updated review of the available options. World J Gastroenterol. 2017;23: Epi procolon [package insert]. Berlin, Germany: Epigenomics AG; Anderson JC, Butterfly LF. Colonoscopy: quality indicators. Clin Translat Gastroenterol. 2015;e77. doi: /ctg Corely DA, Jensen CD, Marks AR, et al. Adenoma detection rate and risk of colorectal cancer and death. N Engl J Med. 2014;370: Kaminski MF, Regula J, Kraszewska W, et al. Quality indicators for colonoscopy and the risk of interval cancer. N Engl J Med. 2010;362: Aranda-Hernandez J, Hwang J, Kandel G. Seeing better -- evidence based recommendations on optimizing colonoscopy adenoma detection rate. World J Gastroenterol. 2016;22: Biecker E, Floer M, Heinecke A, et al. Novel Endocuff-assisted colonoscopy significantly increases the polyp detection rate: a randomized, controlled trial. J Clin Gastroenterol. 2015;49: Abbreviations ACG/ASGE = American College of Gastroenterology/ American Society for Gastrointestinal Endoscopy ADR = adenoma detection rate CMS = Centers for Medicare and Medicaid Services CRC = colorectal cancer CT = computed tomography FDA = US Food and Drug Administration FIT = fecal immunochemical test GI = gastrointestinal HD = high definition NBI = narrow band imaging PCP = primary care provider RCT = randomized controlled trial SSP = sessile serrated polyp US = ultrasound USMSTF = US Multi-Society Task Force Pg.26
Colorectal Cancer Screening
Recommendations from the U.S. Multi-Society Task Force on Colorectal Cancer Colorectal Cancer Screening Rex DK, Boland CR, Dominitz JA, Giardiello FM, Johnson DA, Kaltenbach T, Levin TR, Lieberman D, Robertson
More informationColon Cancer Screening. Layth Al-Jashaami, MD GI Fellow, PGY 4
Colon Cancer Screening Layth Al-Jashaami, MD GI Fellow, PGY 4 -Colorectal cancer (CRC) is a common and lethal cancer. -It has the highest incidence among GI cancers in the US, estimated to be newly diagnosed
More informationColon Polyps: Detection, Inspection and Characteristics
Colon Polyps: Detection, Inspection and Characteristics Stephen Kim, M.D. Assistant Professor of Medicine Interventional Endoscopy Services UCLA Division of Digestive Diseases September 29, 2018 1 Disclosures
More informationColorectal Cancer Screening: Recommendations for Physicians and Patients from the U.S. Multi-Society Task Force on Colorectal Cancer
1016 CLINICAL GUIDELINES CME Colorectal Cancer Screening: Recommendations for Physicians and Patients from the U.S. Multi-Society Task Force on Colorectal Cancer Douglas K. Rex, MD 1, C. R i chard B ol
More informationColorectal Cancer Screening: Recommendations for Physicians and Patients from the U.S. Multi-Society Task Force on Colorectal Cancer
Colorectal Cancer Screening: Recommendations for Physicians and Patients from the U.S. Multi-Society Task Force on Colorectal Cancer Douglas K. Rex, MD, MACG 1, C. Richard Boland, MD 2, Jason A. Dominitz,
More informationScreening & Surveillance Guidelines
Chapter 2 Screening & Surveillance Guidelines I. Eligibility Coloradans ages 50 and older (average risk) or under 50 at elevated risk for colon cancer (personal or family history) that meet the following
More informationObjectives. Definitions. Colorectal Cancer Screening 5/8/2018. Payam Afshar, MS, MD Kaiser Permanente, San Diego. Colorectal cancer background
Colorectal Cancer Screening Payam Afshar, MS, MD Kaiser Permanente, San Diego Objectives Colorectal cancer background Colorectal cancer screening populations Colorectal cancer screening modalities Colonoscopy
More informationThe New Grade A: USPSTF Updated Colorectal Cancer Screening Guidelines, What does it all mean?
The New Grade A: USPSTF Updated Colorectal Cancer Screening Guidelines, What does it all mean? Robert A. Smith, PhD Cancer Control, Department of Prevention and Early Detection American Cancer Society
More informationEarly detection and screening for colorectal neoplasia
Early detection and screening for colorectal neoplasia Robert S. Bresalier Department of Gastroenterology, Hepatology and Nutrition. The University of Texas. MD Anderson Cancer Center. Houston, Texas U.S.A.
More informationThis article is a CME certified activity. To earn credit for this activity visit: /viewarticle/758676
This article is a CME certified activity. To earn credit for this activity visit: /viewarticle/758676 CME Information CME Released: 02/15/2012; Valid for credit through 02/15/2013 Target Audience www.medscape.org
More informationColon Screening in 2014 Offering Patients a Choice. Clark A Harrison MD The Nevada Colon Cancer Partnership
Colon Screening in 2014 Offering Patients a Choice Clark A Harrison MD The Nevada Colon Cancer Partnership Objectives 1. Understand the incidence and mortality rates for CRC in the US. 2. Understand risk
More informationDigestive Health Southwest Endoscopy 2016 Quality Report
Digestive Health 2016 Quality Report Our 2016 our quality and value management program focused on one primary area of interest: Performing high quality colonoscopy High quality Colonoscopy We selected
More informationColorectal Cancer Screening: A Clinical Update
11:05 11:45am Colorectal Cancer Screening: A Clinical Update SPEAKER Kevin A. Ghassemi, MD Presenter Disclosure Information The following relationships exist related to this presentation: Kevin A. Ghassemi,
More informationRetroflexion and prevention of right-sided colon cancer following colonoscopy: How I approach it
Retroflexion and prevention of right-sided colon cancer following colonoscopy: How I approach it Douglas K Rex 1 MD, MACG 1. Indiana University School of Medicine Division of Gastroenterology/Hepatology
More information2. Describe pros/cons of screening interventions (including colonoscopy, CT colography, fecal tests)
Learning Objectives 1. Review principles of colon adenoma/cancer biology that permit successful prevention regimes 2. Describe pros/cons of screening interventions (including colonoscopy, CT colography,
More informationGuidelines for Colonoscopy Surveillance After Screening and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer
Guidelines for Colonoscopy Surveillance After Screening and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer David A. Lieberman, 1 Douglas K. Rex, 2 Sidney J. Winawer,
More informationACG Clinical Guideline: Colorectal Cancer Screening
ACG Clinical Guideline: Colorectal Cancer Screening Douglas K. Rex, MD, FACG 1, David A. Johnson, MD, FACG 2, Joseph C. Anderson, MD 3, Phillip S. Schoenfeld, MD, MSEd, MSc (Epi), FACG 4, Carol A. Burke,
More informationImproving the Adenoma Detection Rate. ADR is a (the) priority quality indicator
Improving the Adenoma Detection Rate Douglas K. Rex, MD, MACG Indiana University School of Medicine Indianapolis, IN ADR is a (the) priority quality indicator Endorsed Adenoma Detection Rate Cecal intubation
More informationImproving Outcomes in Colorectal Cancer: The Science of Screening. Colorectal Cancer (CRC)
Improving Outcomes in Colorectal Cancer: The Science of Screening Tennessee Primary Care Association October 23, 2014 Durado Brooks, MD, MPH Director, Prostate and Colorectal Cancers Colorectal Cancer
More informationJoint Session with ACOFP and Cancer Treatment Centers of America (CTCA): Cancer Screening: Consensus & Controversies. Ashish Sangal, M.D.
Joint Session with ACOFP and Cancer Treatment Centers of America (CTCA): Cancer Screening: Consensus & Controversies Ashish Sangal, M.D. Cancer Screening: Consensus & Controversies Ashish Sangal, MD Director,
More informationAlberta Colorectal Cancer Screening Program (ACRCSP) Post Polypectomy Surveillance Guidelines
Alberta Colorectal Cancer Screening Program (ACRCSP) Post Polypectomy Surveillance Guidelines June 2013 ACRCSP Post Polypectomy Surveillance Guidelines - 2 TABLE OF CONTENTS Background... 3 Terms, Definitions
More informationFREQUENTLY ASKED QUESTIONS
FREQUENTLY ASKED QUESTIONS What is CRC? CRC (CRC) is cancer of the large intestine (colon), the lower part of the digestive system. Rectal cancer is cancer of the last several inches of the colon. Together,
More informationCANCER SCREENING USPSTF AND BEYOND. DeAnn Cummings, MD March 3, 2018
CANCER SCREENING USPSTF AND BEYOND DeAnn Cummings, MD March 3, 2018 OBJECTIVES Review and discuss cancer screening guidelines for: Colorectal CA Prostate CA Breast CA Ovarian CA Secondary prevention, NOT
More informationProf Rupert Leong, Director of Endoscopy, Head of IBD Professor of Medicine UNSW, University of Sydney, Concord Hospital Australia IBDSydney
10:30-10:50 25 Sept 2017 Monday A-PSDE / WEO Colorectal Cancer Screening Committee (CRCSC) Meeting Room S228 (2/F) Prof Rupert Leong, Director of Endoscopy, Head of IBD Professor of Medicine UNSW, University
More informationColon Cancer Screening and Surveillance. Louis V. Antignano, M.D. Wilson Gastroenterology October 11, 2011
Colon Cancer Screening and Surveillance Louis V. Antignano, M.D. Wilson Gastroenterology October 11, 2011 Colorectal Cancer Preventable cancer Number 2 cancer killer in the USA Often curable if detected
More informationDysplasia 4/19/2017. How do I practice Chromoendoscopy for Surveillance of Colitis? SCENIC: Polypoid Dysplasia in UC. Background
SCENIC: Polypoid in UC Definition How do I practice for Surveillance of Colitis? Themos Dassopoulos, M.D. Director, BSW Center for IBD Themistocles.Dassopoulos@BSWHealth.org Tel: 469-800-7189 Cell: 314-686-2623
More informationBenchmarking For Colonoscopy. Technology and Technique to Improve Adenoma Detection
Benchmarking For Colonoscopy Technology and Technique to Improve Adenoma Detection Objectives 1. Review the latest data on performance characteristics and efficacy for colon cancer prevention 2. Highlight
More informationCLINICAL PRACTICE GUIDELINE FOR COLORECTAL CANCER SCREENING
CLINICAL PRACTICE GUIDELINE FOR COLORECTAL CANCER SCREENING This guideline is designed to assist practitioners by providing the framework for colorectal cancer (CRC) screening, and is not intended to replace
More informationQuality ID #343: Screening Colonoscopy Adenoma Detection Rate National Quality Strategy Domain: Effective Clinical Care
Quality ID #343: Screening Colonoscopy Adenoma Detection Rate National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Outcome DESCRIPTION:
More informationColorectal Cancer Screening. Paul Berg MD
Colorectal Cancer Screening Paul Berg MD What is clinical integration? AMA Definition The means to facilitate the coordination of patient care across conditions, providers, settings, and time in order
More informationColorectal Cancer Screening
Colorectal Cancer Screening An Integrated Care Pathway of the Collaborative Care Network Subject Matter Expert: Kevin Wolov, DO Pathway Custodian: Pat Czapp, MD First, a Friendly Reminder... This Integrated
More informationColonoscopy Quality Data
Colonoscopy Quality Data www.dhsgi.com Introduction Colorectal cancer is the second leading cause of cancer related deaths in the United States, in men and women combined. In 2016, there are expected to
More informationColorectal Cancer Screening and Surveillance
1 Colorectal Cancer Screening and Surveillance Jeffrey Lee MD, MAS Assistant Clinical Professor of Medicine University of California, San Francisco jeff.lee@ucsf.edu Objectives Review the various colorectal
More informationImproving you ADR. Robert Enns Colonoscopy Education Day October 2018
Improving you ADR Robert Enns Colonoscopy Education Day October 2018 ADR Applying to CSP Assume 50% ADR in FIT positive patients Out of 40 patients only 20 will have polyps Out of 20 likely 15 will be
More informationEmerging Interventions in Endoscopy. Margaret Vance Nurse Consultant in Gastroenterology St Mark s Hospital
Emerging Interventions in Endoscopy Margaret Vance Nurse Consultant in Gastroenterology St Mark s Hospital Colon Cancer Colon cancer is common. 1 in 20 people in the UK will develop the disease 19 000
More information11/9/2015 OUTLINE. Quality Indicators for the Doctor Performing Screening Colonoscopy: What you should expect from your Endoscopist
Quality Indicators for the Doctor Performing Screening Colonoscopy: What you should expect from your Endoscopist Anil K Sharma MD FACP Professor of Clinical Medicine, University of Rochester Chief of Gastroenterology,
More informationDevices To Improve Colon Polyp Detection
Devices To Improve Colon Polyp Detection ACG/VGS Regional Postgraduate Course Sep 10-11, 2016 Williamsburg, VA VIVEK KAUL, MD, FACG Segal-Watson Professor of Medicine Chief, Division of Gastroenterology
More informationColorectal Cancer Screening: Colonoscopy, Potential and Pitfalls. Disclosures: None. CRC: still a major public health problem
Colorectal Cancer Screening: Colonoscopy, Potential and Pitfalls Disclosures: None Jonathan P. Terdiman, M.D. Professor of Clinical Medicine University of California, San Francisco CRC: still a major public
More informationCRC Risk Factors. U.S. Adherence Rates Cancer Screening. Genetic Model of Colorectal Cancer. Epidemiology and Clinical Consequences of CRC
10:45 11:45 am Guide to Colorectal Cancer Screening SPEAKER Howard Manten M.D. Presenter Disclosure Information The following relationships exist related to this presentation: Howard Manten MD: No financial
More informationCologuard Screening for Colorectal Cancer
Pending Policies - Medicine Cologuard Screening for Colorectal Cancer Print Number: MED208.056 Effective Date: 08-15-2016 Coverage: I.Cologuard stool DNA testing may be considered medically necessary for
More informationSurveying the Colon; Polyps and Advances in Polypectomy
Surveying the Colon; Polyps and Advances in Polypectomy Educational Objectives Identify classifications of polyps Describe several types of polyps Verbalize rationale for polypectomy Identify risk factors
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Kaminski MF, Regula J, Kraszewska E, et al. Quality indicators
More informationUpdates in Colorectal Cancer Screening & Prevention
Updates in Colorectal Cancer Screening & Prevention Swati G. Patel, MD MS Assistant Professor of Medicine Division of Gastroenterology & Hepatology Gastrointestinal Cancer Risk and Prevention Clinic University
More informationImproving Your Adenoma Detection Rate
Improving Your Adenoma Detection Rate JILL TINMOUTH, ASSOCIATE PROFESSOR, UNIVERSITY OF TORONTO JERRY MCGRATH, ASSOCIATE PROFESSOR, MEMORIAL UNIVERSITY OF NEWFOUNDLAND FEB. 11 2017 X CanMEDS Roles Covered
More information2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Outcome High Priority
Quality ID #343: Screening Colonoscopy Adenoma Detection Rate National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Preventive Care 2019 COLLECTION TYPE: MIPS CLINICAL QUALITY
More informationCANCER SCREENING USPSTF AND BEYOND. DeAnn Cummings, MD March 9, 2019
CANCER SCREENING USPSTF AND BEYOND DeAnn Cummings, MD March 9, 2019 OBJECTIVES Review and discuss cancer screening guidelines for: Colorectal CA Prostate CA Breast CA Ovarian CA Secondary prevention, NOT
More informationColon Cancer Screening & Surveillance. Amit Patel, MD PGY-4 GI Fellow
Colon Cancer Screening & Surveillance Amit Patel, MD PGY-4 GI Fellow Epidemiology CRC incidence and mortality rates vary markedly around the world. Globally, CRC is the third most commonly diagnosed cancer
More informationColorectal Cancer Screening Guideline Issue Brief Updated May 30 th, 2018
Colorectal Cancer Screening Guideline Issue Brief Updated May 30 th, 2018 Issue Summary The American Cancer Society has updated its colorectal screening guideline, which have been published in CA: A Journal
More informationMeasure #425: Photodocumentation of Cecal Intubation National Quality Strategy Domain: Effective Clinical Care
Measure #425: Photodocumentation of Cecal Intubation National Quality Strategy Domain: Effective Clinical Care 2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process DESCRIPTION: The
More informationASGE and AGA Issue Consensus Statement on Surveillance and Management of Dysplasia in Patients With Inflammatory Bowel Disease
ASGE and AGA Issue Consensus Statement on Surveillance and Management of Dysplasia in Patients With Inflammatory Bowel Disease DOWNERS GROVE, Ill., (March 5, 2015) The American Society for Gastrointestinal
More informationMeasure #343: Screening Colonoscopy Adenoma Detection Rate National Quality Strategy Domain: Effective Clincal Care
Measure #343: Screening Colonoscopy Adenoma Detection Rate National Quality Strategy Domain: Effective Clincal Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY DESCRIPTION: The percentage
More informationWhat Questions Should You Ask?
? Your Doctor Has Ordered a Colonoscopy. What Questions Should You sk? From the merican College of Gastroenterology www.acg.gi.org Normal colon Is the doctor performing your colonoscopy a Gastroenterologist?
More informationThis article is a CME certified activity. To earn credit for this activity visit:
This article is a CME certified activity. To earn credit for this activity visit: http://cme.medscape.com/viewarticle/716379 cme.medscape.com From MedscapeCME Clinical Briefs Exercise May Improve Cognitive
More informationColorectal Cancer Screening. Daniel C. Chung, MD GI Unit and GI Cancer Genetics Service Massachusetts General Hospital
Colorectal Cancer Screening Daniel C. Chung, MD GI Unit and GI Cancer Genetics Service Massachusetts General Hospital March, 2018 CRC Epidemiology 4th most common malignancy in US (136,000 cases/yr) 2nd
More informationCancer Facts for Men FOR REVIEW ONLY
Cancer Facts for Men Prostate cancer The chance of getting prostate cancer goes up as a man gets older. Most prostate cancers are found in men over the age of 65. For reasons that are still unknown, African
More informationColorectal Cancer Screening in Ohio CHCs. Ohio Association of Community Health Centers
Colorectal Cancer Screening in Ohio CHCs Ohio Association of Community Health Centers 2 1/29/2015 Your Speakers Dr. Ted Wymyslo Ashley Ballard Randy Runyon 3 1/29/2015 Facts 3 rd most common cancer in
More informationLearning and Earning with Gateway Professional Education CME/CEU Webinar Series
Learning and Earning with Gateway Professional Education CME/CEU Webinar Series Best Practices for Colorectal Cancer Screening March 14, 2018 12:00pm 1:00pm Robert A. Smith, PhD Vice President, Cancer
More informationColorectal. The Latest Advances to Improve Adenoma Detection Rates. Sunday, October 15, 2017
Presorted First Class Mail US Postage PAID Permit # 906 Bellmawr NJ Cancer Prevention Distinguished Indiana University Indianapolis, IN University of Kansas School of Medicine Kansas City, MO Editor in
More informationDouglas K. Rex, MD Indiana University Hospital Indianapolis, IN
Serrated Adenomas: What do they mean and what to do about them? Douglas K. Rex, MD Indiana University Hospital Indianapolis, IN Colorectal Cancer Molecular Basis Pathway Frequency Genes MSI Precursor Speed
More informationPage 1. Cancer Screening for Women I have no conflicts of interest. Overview. Breast, Colon, and Lung Cancer. Jeffrey A.
Cancer Screening for Women 2017 Breast, Colon, and Lung Cancer Jeffrey A. Tice, MD Professor of Medicine Division of General Internal Medicine University of California, San Francisco I have no conflicts
More informationHow to start a screening Program? WEO Colorectal Cancer Screening Committee Meeting Brasilia Nov R. Sáenz, FACG,FASGE
How to start a screening Program? WEO Colorectal Cancer Screening Committee Meeting Brasilia Nov 11 2017 R. Sáenz, FACG,FASGE Wheel has been discovered already Policy Planning Thanks to GBD Big Data CRC
More informationPredict, Resect and discard : Yes we can! (at least in some hands)
Diminutive polyps : Real time endoscopic histology Predict, Resect and discard : Yes we can! (at least in some hands) Robert Benamouzig Hôpital Avicenne AP-HP & Paris 13 University France Why it is important?
More informationWhat is Colorectal Cancer?
COLORECTAL CANCER (CRC) What is Colorectal Cancer? Colorectal cancer (also known as colon cancer) is cancer of the colon and/or rectum and occurs when a growth in the lining of the colon or rectum becomes
More informationQuality in Endoscopy: Can We Do Better?
Quality in Endoscopy: Can We Do Better? Erik Rahimi, MD Assistant Professor Division of Gastroenterology, Hepatology, and Nutrition UT Health Science Center at Houston McGovern Medical School Ertan Digestive
More informationMeasure #425: Photodocumentation of Cecal Intubation National Quality Strategy Domain: Effective Clinical Care
Measure #425: Photodocumentation of Cecal Intubation National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY DESCRIPTION: The rate of screening
More informationGIQIC18 Appropriate follow-up interval of not less than 5 years for colonoscopies with findings of 1-2 tubular adenomas < 10 mm
GI Quality Improvement Consortium, Ltd. (GIQuIC) 1 Following is an overview of the clinical quality measures in GIQuIC that can be reported to CMS for the Quality performance category of the Merit-Based
More informationEndoscopic Corner CASE 1. Kimtrakool S Aniwan S Linlawan S Muangpaisarn P Sallapant S Rerknimitr R
170 Endoscopic Corner Kimtrakool S Aniwan S Linlawan S Muangpaisarn P Sallapant S Rerknimitr R CASE 1 A 54-year-old woman underwent a colorectal cancer screening. Her fecal immunochemical test was positive.
More informationQuality Measures In Colonoscopy: Why Should I Care?
Quality Measures In Colonoscopy: Why Should I Care? David Greenwald, MD, FASGE Professor of Clinical Medicine Albert Einstein College of Medicine Montefiore Medical Center Bronx, New York ACG/ASGE Best
More informationWith CRC Screening Rates on the Rise, Quality Control Becomes Center of Attention
print this article In the News ISSUE: OCTOBER 2009 VOLUME: 60:10 With CRC Screening Rates on the Rise, Quality Control Becomes Center of Attention by Monica J. Smith New York In just the past year, New
More informationInterval Cancers: What is Next?
Interval Cancers: What is Next? Douglas Corley, MD, PhD Kaiser Permanente, Northern California Gastroenterologist, TPMG Director of Delivery Science & Applied Research Defining the mission Mercury project:
More informationUK Bowel Cancer screening Dr Voi Shim Wong BsC MD FRCP. Consultant Gastroenterologist Accredited BCSP colonoscopist Whittington + UCL Hospitals
UK Bowel Cancer screening 2017 Dr Voi Shim Wong BsC MD FRCP Consultant Gastroenterologist Accredited BCSP colonoscopist Whittington + UCL Hospitals Bowel Cancer Contents UK Bowel Cancer Screening Programme
More informationWellness Along the Cancer Journey: Healthy Habits and Cancer Screening Revised October 2015 Chapter 7: Cancer Screening and Early Detection of Cancer
Wellness Along the Cancer Journey: Healthy Habits and Cancer Screening Revised October 2015 Chapter 7: Cancer Screening and Early Detection of Cancer Healthy Habits and Cancer Screening Rev 10.20.15 Page
More informationGet tested for. Colorectal cancer. Doctors know how to prevent colon or rectal cancer- and you can, too. Take a look inside.
Get tested for Colorectal cancer Doctors know how to prevent colon or rectal cancer- and you can, too. Take a look inside. 1 If you re 50 or older, you need to get tested for colorectal cancer. It s one
More informationBENEFIT APPLICATION BLUE CARD/NATIONAL ACCOUNT ISSUES
Medical Policy BCBSA Ref. Policy: 2.01.84 Last Review: 11/15/2018 Effective Date: 11/15/2018 Section: Medicine Related Policies 2.01.87 Confocal Laser Endomicroscopy 6.01.32 Virtual Colonoscopy/Computed
More informationMissed Lesions at Endoscopy. Dr Russell Walmsley, MD, FRCP, FRACP Gastroenterologist WDHB Chair Endoscopy Guidance Group for New Zealand
Missed Lesions at Endoscopy Dr Russell Walmsley, MD, FRCP, FRACP Gastroenterologist WDHB Chair Endoscopy Guidance Group for New Zealand Missed Lesions at Endoscopy Is there a problem? With Gastroscopy
More informationKenneth D. Chi, MD Medical Director, GI Lab Advocate Lutheran General Hospital Center for Digestive Health May 7, 2016
Kenneth D. Chi, MD Medical Director, GI Lab Advocate Lutheran General Hospital Center for Digestive Health May 7, 2016 Why have Quality Indicators? Pre-procedure Quality Indicators Intra-procedure Quality
More informationColorectal Cancer: Preventable, Beatable, Treatable. American Cancer Society
Colorectal Cancer: Preventable, Beatable, Treatable American Cancer Society Reviewed/Revised May 2018 What we ll be talking about How common is colorectal cancer? What is colorectal cancer? What causes
More informationChromoendoscopy or Narrow Band Imaging with Targeted biopsies Should be the Cancer Surveillance Endoscopy Procedure of Choice in Ulcerative Colitis
Chromoendoscopy or Narrow Band Imaging with Targeted biopsies Should be the Cancer Surveillance Endoscopy Procedure of Choice in Ulcerative Colitis Bret A. Lashner, M.D. Professor of Medicine Director,
More informationAdvances in Endoscopic Imaging
Advances in Endoscopic Imaging SGNA meeting February 20, 2010 Amar R. Deshpande, MD Asst Professor of Medicine Division of Gastroenterology University of Miami Miller School of Medicine Objectives To recognize
More informationremoval of adenomatous polyps detects important effectively as follow-up colonoscopy after both constitute a low-risk Patients with 1 or 2
Supplementary Table 1. Study Characteristics Author, yr Design Winawer et al., 6 1993 National Polyp Study Jorgensen et al., 9 1995 Funen Adenoma Follow-up Study USA Multi-center, RCT for timing of surveillance
More informationChromoendoscopy as an Adjunct to Colonoscopy
Chromoendoscopy as an Adjunct to Colonoscopy Policy Number: 2.01.84 Last Review: 1/2018 Origination: 7/2017 Next Review: 7/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will not provide
More informationIEHP UM Subcommittee Approved Authorization Guidelines Colorectal Cancer Screening with Cologuard TM for Medicare Beneficiaries
for Medicare Beneficiaries Policy: Based on our review of the available evidence, the IEHP UM Subcommittee adopts the use of Cologuard TM - a multi-target stool DNA test as a colorectal cancer screening
More informationQuality Outcomes for Endoscopy
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/gi-insights/quality-outcomes-for-endoscopy/3744/
More informationCancer Screenings and Early Diagnostics
Cancer Screenings and Early Diagnostics Ankur R. Parikh, D.O. Medical Director, Center for Advanced Individual Medicine Hematologist/Medical Oncologist Atlantic Regional Osteopathic Convention April 6
More informationExperience and challenges of implementing optical diagnosis into clinical practice UK and European Perspective
Experience and challenges of implementing optical diagnosis into clinical practice UK and European Perspective WEO Image Enhanced Endoscopy San Diego, USA Dr James East Consultant Gastroenterologist Honorary
More informationGI CANCER SCREENING- Is It Worth It? Sylvia M. Oats, MSN, APRN, ANP-BC Susan H. Miedecke, MSN, APRN, FNP-BC Gastroenterology Clinic of Acadiana
GI CANCER SCREENING- Is It Worth It? Sylvia M. Oats, MSN, APRN, ANP-BC Susan H. Miedecke, MSN, APRN, FNP-BC Gastroenterology Clinic of Acadiana Life is a sexually transmitted disease, and the mortality
More informationGI Screening/Surveillance in Lynch Syndrome
GI Screening/Surveillance in Lynch Syndrome M Appleyard Royal Brisbane and Women s Hospital Brisbane, Australia GI Disease and Lynch Syndrome What are risks of GI disease in Lynch? Who do we screen for
More informationDr. Coakley, so virtual colonoscopy, what is it? Is it a CT exam exactly?
Virtual Colonoscopy Webcast January 26, 2009 Fergus Coakley, M.D. Please remember the opinions expressed on Patient Power are not necessarily the views of UCSF Medical Center, its medical staff or Patient
More informationIncreasing Colorectal Cancer Screening in Wyoming. Allie Bain, MPH Outreach & Education Supervisor Wyoming Integrated Cancer Services Program
Increasing Colorectal Cancer Screening in Wyoming Allie Bain, MPH Outreach & Education Supervisor Wyoming Integrated Cancer Services Program Overview What is colorectal cancer? What are risk factors for
More informationSupporting Information 2. ESGE QIC Lower GI Delphi voting process: Round 1 Working Group chair: Michal F. Kaminski, Poland
Supporting Information 2. ESGE QIC Lower GI Delphi voting process: Round 1 Working chair: Michal F. Kaminski, Poland Population Interventions Comparator Outcome Additional evidence 1.1 Rate of adequate
More informationGeneral Session 7: Controversies in Screening and Surveillance in Colorectal Cancer
General Session 7: Controversies in Screening and Surveillance in Colorectal Cancer Complexities of Pathological Assessment: Serrated Polyps/Adenomas Carolyn Compton, MD, PhD Professor of Life Sciences,
More informationTips to Improve ADRs during Colonoscopy
Tips to Improve ADRs during Colonoscopy Aasma Shaukat, MD, MPH, FACG GI Section Chief, Minneapolis VAMC Associate Professor, University of Minnesota Outline Why is quality important? Fundamentals of high-quality
More informationDefeating Colon Cancer with Surgery
Defeating Colon Cancer with Surgery Recorded on: September 19, 2012 Alessandro Fichera, M.D. Director, Colorectal Surgical Oncology Program, Seattle Cancer Care Alliance Please remember the opinions expressed
More informationColonoscopy Quality Data 2017
Colonoscopy Quality Data Introduction Colorectal cancer is the second leading cause of cancer related deaths in the United States, in men and women combined. According to the American Cancer Society, in
More informationReduced Carbohydrate Intake May Lower Cardiovascular Risk CME
To Print: Click your browser's PRINT button. NOTE: To view the article with Web enhancements, go to: http://www.medscape.com/viewarticle/516977 This activity is supported by funding from WebMD. Reduced
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Colorectal cancer: colonoscopic surveillance for prevention of colorectal cancer in patients with ulcerative colitis, Crohn
More informationColorectal Cancer Screening
Scan for mobile link. Colorectal Cancer Screening What is colorectal cancer screening? Screening examinations are tests performed to identify disease in individuals who lack any signs or symptoms. The
More informationMeasuring the quality of colonoscopy: Where are we now and where are we going?
Measuring the quality of colonoscopy: Where are we now and where are we going? Timothy D. Imler, MD Division of Gastroenterology and Hepatology, Indiana University School of Medicine, Indianapolis, Indiana
More informationDetect Cervical Cancer ReachMD Page 1 of 7
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More information